-Bloomberg
Wedbush Maintains Outperform on Ascendis Pharma, Lowers Price Target to $117
Wedbush analyst Liana Moussatos maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $128 to $117.
Related Posts
Jefferies Cuts Wayfair Price Target By 40%
Jefferies analyst Jonathan Matuszewski lowered the price target on Wayfair Inc (NYSE:W) to $149 from $247, implying a 1% upside, and kept a…
If You Invested $1,000 In Bitcoin (BTC) During 2017 Peak, Here’s How Much You’d Have Right Now
Bitcoin (CRYPTO: BTC) captured the public and media’s imagination in 2017 when it soared from $1000 at the beginning of the year to $20,000 by December.
